Cardiometabolic complications after androgen deprivation therapy in a man with prostate cancer: effects of 3 years intermittent testosterone supplementation.

Aversa A, Francomano D, Lenzi A

Frontiers in endocrinology16 Feb 2012Cited by 4 (Europe PMC)

PMID22645517PMCIDPMC3355839DOI10.3389/fendo.2012.00017PepBankPUB-22645517

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesSafety outcome
A man with prostate cancer experienced acute myocardial infarction after 6 months of triptorelin plus bicalutamide.
In plain wordsA man with prostate cancer had a heart attack after 6 months of triptorelin plus bicalutamide.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableAcute myocardial infarction
Study
n = 1
Outcome group
Adverse events · Cardiovascular
Source sentences
Summary
After 6 months of treatment, he experienced an acute myocardial infarction and 1 month after hospitalization he came to our outpatient clinic for fatigue, weight gain, and hyperglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
An 80-year-old caucasian man was diagnosed intermediate grade (Gleason 4 + 3) PCa and was treated with continuous ADT with triptorelin plus bicalutamide.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2264551701
02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesSafety outcome
A man treated with triptorelin plus bicalutamide presented with fatigue after myocardial infarction hospitalization.
In plain wordsA man treated with triptorelin plus bicalutamide reported fatigue after hospitalization for a heart attack.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableFatigue
Study
n = 1
Outcome group
Adverse events · Whole body
Source sentences
Summary
After 6 months of treatment, he experienced an acute myocardial infarction and 1 month after hospitalization he came to our outpatient clinic for fatigue, weight gain, and hyperglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
An 80-year-old caucasian man was diagnosed intermediate grade (Gleason 4 + 3) PCa and was treated with continuous ADT with triptorelin plus bicalutamide.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2264551702
03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesSafety outcome
A man treated with triptorelin plus bicalutamide presented with weight gain after myocardial infarction hospitalization.
In plain wordsA man treated with triptorelin plus bicalutamide reported weight gain after hospitalization for a heart attack.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseWeight gain
Study
n = 1
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
After 6 months of treatment, he experienced an acute myocardial infarction and 1 month after hospitalization he came to our outpatient clinic for fatigue, weight gain, and hyperglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
An 80-year-old caucasian man was diagnosed intermediate grade (Gleason 4 + 3) PCa and was treated with continuous ADT with triptorelin plus bicalutamide.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2264551703
04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesSafety outcome
A man treated with triptorelin plus bicalutamide presented with hyperglycemia after myocardial infarction hospitalization.
In plain wordsA man treated with triptorelin plus bicalutamide had high blood sugar after hospitalization for a heart attack.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableHyperglycemia
Study
n = 1
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
After 6 months of treatment, he experienced an acute myocardial infarction and 1 month after hospitalization he came to our outpatient clinic for fatigue, weight gain, and hyperglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
An 80-year-old caucasian man was diagnosed intermediate grade (Gleason 4 + 3) PCa and was treated with continuous ADT with triptorelin plus bicalutamide.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2264551704
05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesSafety outcome
In a man previously treated with triptorelin plus bicalutamide, serum testosterone remained 0.5 ng/mL after 3 months of ADT withdrawal.
In plain wordsIn a man previously treated with triptorelin plus bicalutamide, testosterone remained low after treatment withdrawal.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicablePersistent testosterone suppression after withdrawal
Study
n = 1
Outcome group
Adverse events · Endocrine and hormones
Measurements
Serum testosterone
0.5 ng/mL
3 months after ADT withdrawal
Source sentences
Summary
Due to iatrogenic hypogonadism, we decided to proceed with IAB, but after 3 months ADT withdrawal his serum testosterone (T) was still 0.5 ng/mL.
1 context sentence(design, population, supporting numbers)
Summary · context
An 80-year-old caucasian man was diagnosed intermediate grade (Gleason 4 + 3) PCa and was treated with continuous ADT with triptorelin plus bicalutamide.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2264551705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.